Four years before dabrafenib appeared on an NHS approvals list, Lesley Coombs was given the drug through a compassionate access scheme, ten days ahead of planned radiotherapy for a tumour that chemotherapy had failed to shift. Within three days it had begun to shrink. The radiotherapy was shelved and Coombs, now 69, has remained in remission since, continuing to cycle forty miles and walk long distances near her home in Cambridgeshire. Her case sat outside routine NHS funding for years, reliant on the manufacturer's discretion rather than any settled commissioning pathway. That gap has now closed. From this month, NHS England has approved dabrafenib for BRAF V600E-positive histiocytic neoplasms and a combination of brentuximab vedotin and bendamustine for children and young people with relapsed or treatment-resistant Hodgkin lymphoma, extending routine access to around two hundred patients a year.

The clinical case is not in question. Roughly one in ten children with high-risk histiocytic disease die within a year without effective treatment, and seven in ten adults die within five years. About 1,800 people in England are affected by Hodgkin lymphoma each year, and anywhere from a tenth and a third of them relapse or do not respond to conventional treatment. The path these medications took to get to patients merits closer examination than the headline numbers. Both were assessed through the Clinical Priorities Advisory Group, the specialised commissioning body that handles treatments falling outside the National Institute for Health and Care Excellence's ordinary evaluation, often because they are not licensed for the specific condition being treated. CPAG does not itself make funding decisions. It ranks clinical benefit against cost and passes recommendations up through the National Commissioning Group and ultimately the NHS England Board, working within a discretionary specialised commissioning budget that must stretch across dozens of competing rare disease proposals each year.

That framework is more important than most people realise. Despite five years of an independent advisory council suggesting treatment for dozens of high-risk patients, dabrafenib's usage in histiocytic neoplasms remained in financing limbo. Dabrafenib was already licensed for melanoma caused by the same BRAF mutation. The commissioning policy underpinning this month's decision was itself only published in January, after a slower administrative process than the clinical urgency implied. For a health system still absorbing the reabsorption of NHS England into the Department of Health and Social Care, and still working through what the 10 Year Health Plan means for specialised services, the CPAG pathway is likely to face more traffic rather than less. Genomic medicine keeps producing treatments defined by mutation rather than tumour site, and NICE's technology appraisal process was not built with that granularity in mind. Increasingly, CPAG becomes the default route for precisely the mutation-specific therapies that oncology is moving towards, and its prioritisation rounds, which weigh dozens of unfunded rare disease proposals against a fixed discretionary pot, will determine how quickly patients like the fifteen or so new high-risk histiocytosis cases identified each year actually get treated.

There is also a delivery dimension that NHS leaders should not overlook. Dabrafenib is taken as a tablet at home rather than through hospital-based infusion, and the department overseeing specialised commissioning has been explicit that this reduces disruption for patients. In a system still managing elective backlogs and bed pressure, oral targeted therapies that shift treatment out of hospital settings carry an operational value that rarely features in the clinical framing of these announcements. Since CPAG functions within an established discretionary budget rather than new expenditure, the clearance does not indicate that the NHS has secured new funding for uncommon malignancies. It is that the machinery for evaluating genetically defined, ultra-rare treatments is being tested at a pace it was not originally designed for, and the patients most exposed to that mismatch are precisely the ones with the least room to wait.